RT Journal Article
SR Electronic
T1 Genome-wide tandem repeat expansions contribute to schizophrenia risk
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.17.21267642
DO 10.1101/2021.12.17.21267642
A1 Bahareh A Mojarad
A1 Worrawat Engchuan
A1 Brett Trost
A1 Ian Backstrom
A1 Yue Yin
A1 Bhooma Thiruvahindrapuram
A1 Linda Pallotto
A1 Mahreen Khan
A1 Giovanna Pellecchia
A1 Bushra Haque
A1 Keyi Guo
A1 Tracy Heung
A1 Gregory Costain
A1 Stephen W Scherer
A1 Christian R Marshall
A1 Christopher E Pearson
A1 Anne S Bassett
A1 Ryan KC Yuen
YR 2021
UL http://medrxiv.org/content/early/2021/12/21/2021.12.17.21267642.abstract
AB Tandem repeat expansions (TREs) can cause neurological diseases but their impact in schizophrenia is unclear. Here we analyzed genome sequences of adults with schizophrenia and found that they have a higher burden of TREs that are near exons and rare in the general population, compared with non-psychiatric controls. These TREs are disproportionately found at loci known to be associated with schizophrenia from genome-wide association studies, in individuals with clinically-relevant genetic variants at other schizophrenia loci, and in families where multiple individuals have schizophrenia. Our findings support the involvement of genome-wide rare TREs in the polygenic nature of schizophrenia.Competing Interest StatementThe authors have declared no competing interest.Funding StatementR.K.C.Y. is supported by The Hospital for Sick Children's Research Institute, SickKids Catalyst Scholar in Genetics, Brain Canada, The Azrieli Foundation, the University of Toronto McLaughlin Centre and the Nancy E.T. Fahrner Award. This work was also supported by the Canadian Institutes of Health Research (CIHR) (MOP-89066 to A.S.B., MOP-111238 to A.S.B., PJT-175329 to R.K.C.Y.), and a Canada Research Chair in Schizophrenia Genetics and Genomic Disorders (Tier 1, 2009-2016 to A.S.B.). A.S.B. holds the Dalglish Chair in 22q11.2 Deletion Syndrome at the University Health Network and University of Toronto. B. Trost was funded by the Canadian Institutes for Health Research Banting Postdoctoral Fellowship and the Brain Canada Canadian Open Neuroscience Platform Research Scholar Award. B.A.M. was supported by the Restracomp Award from The Hospital for Sick Children.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Research Ethics Board at the Centre for Addiction and Mental Health (CAMH) (151/2002-02) and other local REBs. Written informed consent was obtained for all participantsI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe 1000G genome-sequencing data are publicly available via Amazon Web Services (s3://1000genomes/1000G_2504_high_coverage/data). Other data produced in the present work are contained in the manuscript.